On April 6, 2022 AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment of solid cancers, reported that it will present an abstract in a poster session at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in New Orleans, Louisiana, which is being held April 8 – 13 (Press release, AffyImmune Therapeutics, APR 6, 2022, View Source [SID1234611550]). Presented findings will highlight research using AffyImmune’s Tune & Track platform for the affinity tuning of the interaction between CAR T cells and cancer antigen, tracking of CAR T cells in real-time, and armoring of CAR T cells with cytokines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the abstract and poster are as follows:

Title: Focused IL-12 cytokine delivery enhances function of affinity-tuned and real-time tracked ICAM-1-specific CAR T cells in solid tumors
Presenting Author: Michael Gallagher, PhD, Scientist
Session Category: Adoptive Cell Therapy 1
Poster Number: 558/12
Abstract Number: 4978
Presentation Type: Poster
Date, Time, and Location: Sunday, April 10, 1:30 – 5:00 pm, Poster Section 36